Abstract
Diabetes increases the risk of cardiovascular disease; however, this risk is further increased as a result of other factors. This observation is particularly relevant with regard to lipid abnormalities. Although diabetic dyslipidemia is characterized by hypertriglyceridemia, low HDL-cholesterol, and small dense LDL particles, the main determinant of the role of dyslipidemia in the prognosis of diabetics is LDL cholesterol. In recent years, LDL cholesterol targets have become progressively lower, and most current recommendations establish an LDL cholesterol target of <70 mg/dL for diabetics. This target can only be achieved using potent statins at adequate doses. Although it has been suggested that statins may interfere with glycemic metabolism, the benefits of reducing LDL cholesterol by statins are much greater than this possible deleterious effect.
Rosuvastatin is one of the most potent statins available. Several studies have shown that it effectively reduces LDL cholesterol to recommended targets in diabetics. Moreover, rosuvastatin modestly increases HDL cholesterol and decreases triglycerides. The risk of side effects is low, as is the risk of interactions with other drugs.
In this manuscript, the efficacy and safety profile of rosuvastatin in diabetic population is reviewed.
Keywords: Diabetes, efficacy, HDL-cholesterol, LDL cholesterol, lipid profile, lipids, rosuvastatin, safety, statins, total cholesterol, treatment, triglycerides.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Rosuvastatin and Diabetes: When the Evidences Talk
Volume: 11 Issue: 2
Author(s): Vivencio Barrios and Carlos Escobar
Affiliation:
Keywords: Diabetes, efficacy, HDL-cholesterol, LDL cholesterol, lipid profile, lipids, rosuvastatin, safety, statins, total cholesterol, treatment, triglycerides.
Abstract: Diabetes increases the risk of cardiovascular disease; however, this risk is further increased as a result of other factors. This observation is particularly relevant with regard to lipid abnormalities. Although diabetic dyslipidemia is characterized by hypertriglyceridemia, low HDL-cholesterol, and small dense LDL particles, the main determinant of the role of dyslipidemia in the prognosis of diabetics is LDL cholesterol. In recent years, LDL cholesterol targets have become progressively lower, and most current recommendations establish an LDL cholesterol target of <70 mg/dL for diabetics. This target can only be achieved using potent statins at adequate doses. Although it has been suggested that statins may interfere with glycemic metabolism, the benefits of reducing LDL cholesterol by statins are much greater than this possible deleterious effect.
Rosuvastatin is one of the most potent statins available. Several studies have shown that it effectively reduces LDL cholesterol to recommended targets in diabetics. Moreover, rosuvastatin modestly increases HDL cholesterol and decreases triglycerides. The risk of side effects is low, as is the risk of interactions with other drugs.
In this manuscript, the efficacy and safety profile of rosuvastatin in diabetic population is reviewed.
Export Options
About this article
Cite this article as:
Barrios Vivencio and Escobar Carlos, Rosuvastatin and Diabetes: When the Evidences Talk, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (2) . https://dx.doi.org/10.2174/1871525711311020007
DOI https://dx.doi.org/10.2174/1871525711311020007 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Health Benefits of Honey: Implications for Treating Cardiovascular Diseases
Current Nutrition & Food Science Tolerability of Amine Uptake Inhibitors in Urologic Diseases
Current Drug Safety Global Account of Barriers and Facilitators of Physical Activity Among Patients with Diabetes Mellitus: A Narrative Review of the Literature
Current Diabetes Reviews Reactive Oxygen Species in Vascular Wall
Cardiovascular & Hematological Disorders-Drug Targets Heat Shock Protein-60 and Risk for Cardiovascular Disease
Current Pharmaceutical Design Antiplatelet and Anticoagulation Strategies in the Prevention and Treatment of Ischemic Stroke
Current Pharmaceutical Design Inflammation Fueling Atrial Fibrillation Substrate: Seeking Ways to "Cool" the Heart
Medicinal Chemistry Sleep Duration as a Risk Factor for Cardiovascular Disease- a Review of the Recent Literature
Current Cardiology Reviews Lipid Messengers as Targets for Antiangiogenic Therapy
Current Pharmaceutical Design Biomarkers in Cardiomyopathies and Prediction of Sudden Cardiac Death
Current Pharmaceutical Biotechnology Current Status of Hormone Replacement Therapy in Post Menopausal Women
Current Drug Therapy Is Peri-Operative Isolated Systolic Hypertension (ISH) a Cardiac Risk Factor?
Current Cardiology Reviews Activation of the Liver X Receptor Inhibits Th17 and Th1 Responses in Behcet`s Disease and Vogt-Koyanagi-Harada Disease
Current Molecular Medicine Nanomedicine Against Malaria
Current Medicinal Chemistry Resident and Non-Resident Stem Cells in Acute Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets The Coronary Artery Risk Detection in Appalachian Communities (CARDIAC) Project: An 18 Year Review
Current Pediatric Reviews Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets Colesevelam: A New and Improved Bile Acid Sequestrant?
Current Pharmaceutical Design Biomarkers of Oxidative Stress and the Relationship to Cigarette Smoking
Mini-Reviews in Organic Chemistry Understanding the Molecular and Cellular Changes Behind Aortic Valve Stenosis
Current Pharmaceutical Biotechnology